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Summary This short review on current treatment
options in chronic myeloid leukemia (CML) in the
chronic phase summarizes the latest version of the
ELN treatment recommendations dating from 2013
and indicates treatment situations not yet reflected
in these recommendations. Daily practice in CML
management is complicated by the recently observed
treatment-emergent vascular and pulmonary adverse
events in second- or later-generation tyrosine kinase
inhibitors (TKIs), the lack of guidance with respect
to the best TKI for initial treatment, as well as the
optimal TKI sequence because no prospective ran-
domized comparative data for second- and third-gen-
eration TKIs are available. Physicians have to balance
the efficacy issues and safety aspects of the respec-
tive TKI and consider patient-specific factors such
as comorbidities. Patients with any cardiovascular or
pulmonary disease or treatment-requiring cardiovas-
cular risk factor should receive nilotinib or ponatinib
only if risk factors and comorbidities are treated
accordingly and are further monitored. If these co-
morbidities are insufficiently controlled, other TKIs
might be preferred. Dasatinib treatment should be
critically evaluated in patients with pulmonary dis-
ease and other TKIs might be preferred in this setting.
For as long as CML treatment is considered to be
maintained lifelong, and no survival benefit for later-
generation TKIs has been demonstrated, safety issues
dominate the choice of treatment options. The con-
cept of discontinuing TKI treatment after achieving
a deep molecular response might in future change
these considerations.
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The introduction of tyrosine kinase inhibitors (TKIs)
for the treatment of chronic myeloid leukemia (CML)
led to a near-normal life expectancy of patients.
Alongside this therapeutic success, minimal residual
disease quantification by BCR-ABL1 monitoring was
shown to be predictive of survival and thus molecular
remission became the cornerstone of the treatment
goals as recommended by the ELN (see Table 1) and
National Comprehensive Cancer Network (NCCN).
Currently five different TKIs are approved for CML
treatment. Imatinib and the two second-generation
TKIs dasatinib and nilotinib are recommended and
approved for first-line treatment. In the case of in-
tolerance, the use of any other TKI approved for first-
line therapy is recommended. Patients in whom treat-
ment has failed can in principle receive any other TKI
than imatinib. However, according to the European
Medicines Agency (EMA) indications, patients either
must have failed a prior treatment with dasatinib or
nilotinib (ponatinib), or a second-line treatment with
imatinib, dasatinib, or nilotinib would have to be un-
suitable (bosutinib). An exception is the occurrence
of a T315I-mutation of BCR-ABL1, against which no
other TKI than ponatinib has shown activity [1].
First-line treatment
In most cases physicians have to choose between
imatinib, dasatinib, and nilotinib for first-line treat-
ment. However, which of these is the best to start
with in order to achieve the defined treatment goals
remains an unsolved issue. Owing to the lack of ran-
domized direct comparison of dasatinib and nilotinib
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Table 1 ELN 2013 treatment recommendations
Time Optimal Warning Failure
Baseline – High-risk major route CCA/Ph+ –
3 months BCR-ABLIS < 10%*





6 months BCR-ABLIS < 1%*





12 months BCR-ABLIS < 0.1%*
(MMR)
BCR-ABLIS 0.1–1%* BCR-ABLIS > 1%*
Ph+ > 0%
>12 months MMR or better CCA/Ph-(-7, or7q-) Loss of CHR Loss of CCyR Loss of
MMR, confirmed**
Mutations CCA/Ph+
At 1st-line failure – NoCHR
Loss of CHR on imatinib
Lack of CyRto 1st-line TKI high-risk
–




NoCHR, or Ph+ > 95%, or New muta-
tions
6 months of 2nd-line BCR-ABLIS < 10%*













>12 months of 2nd-line MMR or better CCA/Ph-(-7or7q-) or
BCR-ABLIS > 0.1%





**in 2 consecutive tests, of which one ≥1%
the choice of the initial TKI is based on balancing the
risk of progression against safety issues of the specific
TKI in consideration. In the case of high-risk patients
according to SOKAL, HASFORD, or EUTOS score, sec-
ond-generation TKIs (2G-TKIs) are often preferred
[2–4], although a newer meta-analysis does not seem
to support this approach [5].
Both, the ENESTnd [6] and the DASION [7] trial
have shown higher efficacy of the respective 2G-TKIs
(nilotinib and dasatinib) when compared with ima-
tinib. Based on data on these and other trials, major
molecular response (MMR) rates at 12 months can
be expected to be 46% and 51% (vs. 28% and 27% for
imatinib) and deepmolecular remissions at 5-year fol-
low-up were observed in 42% and 54% of patients for
dasatinib and nilotinib (vs 3% and 1% for imatinib),
respectively.
However, the estimated overall 5-year survival was
not significantly different from that of the correspond-
ing imatinib-treated groups (91% and 92.2% for dasa-
tinib and nilotinib, respectively, compared with 90%
and 91%). In addition, neither the greater percent-
age of patients who achieved early molecular response
(EMR: <10% BCR-ABL1IS at 3 months of treatment)
under 2G-TKI treatment [8, 9] nor the lower rate of
progressions into an accelerated or blastic phase ob-
served under this treatment has translated into an
overall survival benefit.
Therefore, standard use of 2G-TKIs instead of ima-
tinib in first-line treatment is controversial and pa-
tients might be overtreated when receiving a 2G-TKI.
Provided that TKI treatment in CML has to be lifelong,
safety issues have to take precedence over aspects of
efficacy as long as survival is not affected.
Some adverse events impact on the choice of the
TKI treatment in particular as they, although rare,
result in severe and irreversible morbidity in a certain
group of patients. Such events are arterial cardio-
and cerebrovascular thromboembolic events as well
as occlusive events of the peripheral arteries, which
were observed under both nilotinib and ponatinib
treatment, venous thrombotic events reported under
ponatinib, and the occurrence of pleural effusions
and pulmonary arterial hypertension that is associ-
ated with dasatinib treatment. Since the presence
of cardiovascular risk factors increases the risk of
arterial occlusive events occurring under nilotinib
and ponatinib treatment [10, 11], these should be
corrected. However, therapy with either nilotinib or
ponatinib per se in the absence of any other indica-
tion for treating these risk factors is no reason to start
such treatment [12]. In addition, there are no data
on whether such a preemptive treatment can reduce
vascular occlusive events.
For low-risk patients, therefore, treatment with
imatinib appears to be reasonable. Similarly, in
high-risk patients with ongoing and uncontrolled
cardiovascular comorbidities, imatinib or dasatinib
treatment might be preferred to nilotinib (or in later
treatment lines, ponatinib). By contrast, high-risk
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Table 2 Management of adverse events (AE)
General approach
Grade Recommendation
Grade 1 No change in TKI treatment, specific AE treatment
Grade 2 Withholding TKI until AE resolves to <grade 2, restart at same dose if first episode otherwise restart TKI at reduced dose. Initial
continuation of TKI may be possible under specific AE treatment; however, if the AE does not resolve the TKI should be withheld
Grade 3 Withholding TKI until AE resolves to grade of at least <grade 3 and restart TKI at next lower dose level or withhold TKI until AE
<grade 2 but then restart at same dose level. If AE duration ≥4 weeks, discontinue and switch TKI, similarly switch in the case of
third episode of same AE
Grade 4 Discontinue current TKI and switch to another TKI
Table 3 Clinically relevant BCR-ABL1 mutations
Mutation Imatinib Dasatinib Nilotinib Bosutinib Ponatinib
G250E Efficacy ↓ – – Efficacy ↓ –
Q252H Efficacy ↓ Efficacy ↓ – – –
Y253F/H Efficacy ↓ – Efficacy ↓ – –
E255K/V Efficacy ↓ Efficacy ↓ Efficacy ↓ Efficacy ↓ Efficacy ↓
T315I Ineffective Ineffective Ineffective Ineffective –
F317L/V/I/C Efficacy ↓ Efficacy ↓ – – –
F355V – – Efficacy ↓ – –
H396R Efficacy ↓ – – – Efficacy ↓
V299L Efficacy ↓ Efficacy ↓ – Efficacy ↓ –
T315A – Efficacy ↓ – – –
F359C/I/C Efficacy ↓ Efficacy ↓ – – –
In bold print mutations assumed to be clinically relevant in most cited references
↓ means decreased
patients with cardiovascular risk factors or controlled
cardiovascular comorbidities might receive a later-
generation TKI provided that treatment of the cardio-
vascular risk factors is continued and a close mon-
itoring of the cardiovascular and metabolic state is
available. Such monitoring should include at least a
3- to 6-monthly measurement of ankle–brachial index
and of the HbA1C. For high-risk patients with pul-
monary comorbidities, other 2G-TKIs than dasatinib
should be preferred.
Adverse events
In general TKIs have a good safety profile; neverthe-
less, serious adverse events (AEs) occur and even fatal
events have been described. Since the latter are so rare
and the former are often of mild severity, physicians’
alertness for AEs in TKI treatment may have dwin-
dled. The ELN established a set of recommendations
for AE management [12] and the general approach is
summarized in Table 2, but more details are beyond
the scope of this introduction. Experience in AE man-
agement is essential to help overcome any reluctance
in re-starting and re-escalating the TKI dose once an
AE has occurred. A recent trial on optimizing nilotinib
treatment demonstrated that in 26.4% of patients who
had their dose previously reduced, no attempt to re-
escalate the dose was undertaken. In this group only
57.9% achieved an MMR at 24 months while 84.8% of
patients in whom re-escalation was tolerated achieved
this response level [13]. Dose re-escalation might be of
particular importance in patients in whom cytopenias
triggered a dose reduction, because myelosuppression
in TKI treatment represents a slow recovery of normal
stem cell function from leukemia-induced suppres-
sion rather than a true toxic effect of TKIs. Newly de-
veloping or progression of previously controlled car-
diovascular or pulmonary diseases under nilotinib or
ponatinib TKI treatment requires a change of the TKI
used.
Second- and later-line treatments
Intolerance of or resistance to a specific TKI usually
requires a switch to another treatment line. At the
5-year update for the DASISION and ENESTnd trials,
39% and 40.1% of patients were no longer still on dasa-
tinib or nilotinib treatment (vs. 37% and 50.2% in the
respective Imatinib groups). If patients do not achieve
a treatment milestone or lose a previously attained re-
sponse, the underlying reason has to be determined to
allow for an informed choice of the next TKI. The life-
long treatment concept and the mainly asymptomatic
disease course prior to treatment start can impact on
treatment adherence. The latter is a major factor of
therapeutic success, as was shown by several groups
[14–17]. While measurement of TKI serum levels – if
available – might help to identify the problem, con-
fronting the patient with the results might compro-
mise the physician–patient relationship, which as in
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Fig. 1 TKI Treatment
choices
any long-term treatment is of particular importance
to establish and maintain treatment adherence.
Resistance to TKI treatment occurs in 20–30% of pa-
tients in the chronic phase of disease and is in up to
50% of cases mediated by BCR-ABL1 mutations [13].
In vitro sensitivity testing of the more than 100 known
BCR-ABL1 mutations [3, 18, 19] to different TKIs can
be informative, but the results do not in all cases re-
flect clinical experience. In Table 3 the clinically most
important mutations are listed (reviewed in [3, 18,
19]).
In general, second-line TKI treatment is based on
the BCR-ABL1 mutation status where applicable and
otherwise on the TKI safety profile and patient-spe-
cific factors (see previous section).
In terms of efficiency, complete cytogenetical re-
sponse (CCyR) rates were 44–53% for dasatinib and
31–45% for nilotinib, while MMR rates of 29–43% and
28% are reported for dasatinib and nilotinib, respec-
tively [20–22]. Bosutinib after imatinib failure demon-
strated CCyR rates of 41–48% [20, 23] and MMR rates
of 64%. Ponatinib data refer [24] to a highly pretreated
population with 58% patients having received three
and more TKIs prior to this ponatinib. In this setting,
CCyR and MMR rates were 53% and 39%, respectively.
Overall survival rates were reported to be 70–74% and
78% at the 6-year follow-up for dasatinib and nilo-
tinib, respectively. With a much shorter follow-up of
2 years, the overall survival was 92% for bosutinib and
86% for ponatinib.
There are no recommendations for TKI choice in
third- or later-line treatment (Fig. 1) due to the few
clinical trials in these settings. However, the efficacy of
bosutinib, which shares its dual SRC/ABL-inhibitory
activity with dasatinib, is markedly reduced (CCyR
17% vs. 54% and MCyR 43% vs. 78%) after imatinib
and dasatinib failure compared with its use in dasa-
tinib-naïve patients, e. g., those having failed imatinib
and nilotinib [25, 26].
Beyond standard treatment
There are several new or nonstandard treatment ap-
proaches worth mentioning:
● ABL001 is a new class of TKI that is not yet approved
for CML treatment [27].
● The efficacy of TKI–interferon combinations [28] is
superior to TKI monotherapy.
● High-dose imatinib is superior to standard dose
in first-line therapy [29] and optimization of the
imatinib dose according to plasma levels markedly
increased MMR rates (76% vs. 46–56%) [30]. This
might impact treatment decisions in particular once
generic imatinib is available.
● Provided the maturing body of evidence supporting
its, feasibility treatment-free remission [31] might
become part of the standard treatment options and
therefore it is noteworthy that more patients under
2G-TKIs than under imatinib 400mg QD achieved
the required deep molecular responses.
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